Tropic, a UK-based agricultural technology firm, has closed an oversubscribed $105 million Series C funding round to advance its gene-edited tropical crops. Co-led by Forbion and Corteva, the investment will fuel the global scale-up of its innovative banana and rice varieties. This capital injection underscores growing confidence in biotechnology's role in creating a more sustainable and secure food system.
Investor Confidence and Strategic Leadership
The round saw significant participation from Just Climate and IQ Capital, alongside new investors ABN Amro and Invest International. Existing backers, including Temasek and Five Seasons Ventures, also reaffirmed their support for the company's vision. The strong investor interest highlights the value of Tropic's technology in addressing pressing agricultural challenges.
As part of the financing, Tropic is strengthening its governance with three new board members. Joy Faucher from Forbion, Tom Greene from Corteva, and Siddarth Shrikanth from Just Climate will bring extensive industry experience. Their strategic guidance will be instrumental as Tropic expands its commercial operations and global footprint.
Breakthroughs in Agricultural Technology
This financial milestone follows a year in which Tropic introduced the first new commercial banana varieties in over seven decades. Its non-browning banana was named one of TIME Magazine’s Best Inventions of 2025, while another variety boasts an extended shelf life. These products have generated demand that already outpaces the company's current production capacity.
Tropic's innovations are powered by its proprietary GEiGS® platform, which merges gene editing tools like CRISPR with natural gene silencing. This approach enables the development of non-transgenic crops with improved traits like disease resistance and enhanced durability. The technology is central to the company's mission of developing healthier and more robust crop varieties.
Addressing Critical Global Food Challenges
A key application of this technology is developing bananas resistant to Panama Disease (TR4), a fungus threatening the global supply. Tropic has made substantial progress in this area, with plans for commercial deployment of a resistant variety starting in 2027. This initiative is crucial for safeguarding a vital food source and the livelihoods of millions of farmers.
Gilad Gershon, CEO of Tropic, stated that the funding is a powerful endorsement of the company's ability to deliver breakthrough products. He noted that 2025 proved the technology's immediate impact, moving beyond future promises to current market solutions. This investment will accelerate the scaling of production to meet high demand for its existing varieties.
Future Growth and Expansion Plans
The new capital will be directed toward expanding large-scale plant production capabilities and reinforcing global supply chains. Tropic aims to solidify commercial partnerships across major export markets to ensure its innovative crops reach growers efficiently. This strategic allocation of funds supports the company's transition into a major commercial player.
Beyond its banana portfolio, the investment will fast-track development in the company's rice program and facilitate expansion into other essential crops. Tropic intends to leverage its platform to tackle a broader spectrum of food supply challenges. This diversification is a core part of its long-term strategy to build a leading tropical seeds company.
This successful Series C funding round positions Tropic to make a significant impact on global agriculture and food security. By scaling its proven gene-editing technology, the company is poised to deliver sustainable solutions, reduce food waste, and build resilience against crop diseases. The investment marks a pivotal moment for Tropic as it accelerates its mission to reshape tropical farming.